Skip to main content
Premium Trial:

Request an Annual Quote

Advion BioSciences Signs $9M Service Contract with Top-10 Pharma

NEW YORK, Dec. 16 (GenomeWeb News) - Advion BioSciences said today that it has signed a three-year mass spectrometry services contract worth $9 million with an undisclosed "top-10 pharmaceutical company."

Advion will provide scientists and instrumentation to support the pharmaceutical client's bioanalytical method development, method validation, and sample analysis programs, the company said.

The agreement also provides the client an option to increase its level of resources during the life of the contract.

Stephen Lowes, Advion's vice president of bioanalysis, called the deal the "first of its kind" for the company. "The contract offers a resource model that could be extended to other clients in an environment where top-tier bioanalytical experience is in high demand," he said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.